{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '6.2.1.', 'End of Treatment', 'An end of treatment (EOT) evaluation will be performed for subjects who are withdrawn from', 'treatment for any reason as soon as possible after the decision to permanently discontinue', 'treatment has been made. The end of treatment (Visit 9) assessments will also be performed for', 'subjects who complete the study.', 'The following evaluations will be performed as specified in the Table of Events:', 'Weight, waist circumference', 'Vital signs', 'Concomitant medications and therapies evaluation', 'Adverse event evaluation (through 28 days past last dose of apremilast)', 'Clinical laboratory evaluations', 'Serum pregnancy test for females of childbearing potential (B-subunit of human chorionic', 'gonadotropin [Serum \u00df-hCG])', 'Counseling about pregnancy precautions and the potential risks of fetal exposure must be', 'conducted', 'Return and count IP tablets', 'Efficacy assessment', '6.3.', 'Follow-up Period', '6.3.1.', 'Post-Treatment Observational Follow-up', 'All subjects will be followed for 28 days after the last dose of apremilast for AE reporting , as', 'well as all SAEs made known to the Investigator at any time following the protocol-required', 'reporting period or after end of study, as described in Section 10.1. A 4-week post-treatment', 'observational follow-up will be conducted by telephone at Week 56 for subjects who complete', 'the 52-week study treatment or 4 weeks after study treatment discontinuation.', '6.4.', 'Efficacy Assessments', 'The following assessments will be conducted as outlined in the Table of Events, Table 3.', '6.4.1.', 'The Dermatology Life Quality Index (DLQI)', 'The DLQI (Finlay, 1994) will be assessed by the subject upon arrival at the site', 'before any other procedures or assessments are performed. The DLQI was developed', 'as a simple, compact, and practical questionnaire for use in a dermatology clinical', 'setting to assess limitations related to the impact of skin disease (Finlay, 1994). The', \"instrument contains 10 items pertaining to the subject's skin. With the exception of\", 'Item Number 7, the subject responds on a four-point scale, ranging from \"Very', 'Much\" to \"Not at All.\" Item Number 7 is a multi-part item, the first part of which', \"ascertains whether the subject's skin prevented them from working or studying (Yes\", 'or No), and if \"No,\" then the subject is asked how much of a problem the skin has', 'Confidential and Proprietary', '34', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'been at work or study over the past week, with response alternatives being \"A lot,\"', '\"A little,\" or \"Not at all.\"', 'The DLQI total score has a possible range from 0 to 30, with 30 corresponding to the', 'worst quality of life, and 0 corresponding to the best score. The developers suggest', 'that the DLQI can be grouped into six subscales: symptoms and feelings, daily', 'activities, leisure, work/school, personal relationships, and treatment. Scores for four', 'of the subscales (symptoms and feelings, daily activities, leisure, and personal', 'relationships) range from 0 to 6; scores for two of the subscales (work/school and', 'treatment) range from 0 to 3. Higher scores correspond to poorer quality of life. See', 'Appendix B.', '6.4.2.', 'Static Physicians Global Assessment (sPGA) of Visible Locations', 'The sPGA is the assessment by the Investigator of the overall disease severity at the', 'time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe),', 'incorporating an assessment of the severity of the three primary signs of the disease:', 'erythema, scaling and plaque elevation. In this study, sPGA is used to evaluate', 'psoriasis only in visible locations, defined as dorsal hand, face, neck and hairline.', 'When making the assessment of overall severity, the investigator should factor in', 'areas that have already been cleared (ie, have scores of 0) and not just evaluate', 'remaining lesions for severity, ie, the severity of each sign is averaged across all areas', 'of involvement, including cleared lesions. In the event of different severities across', 'disease signs, the sign that is the predominant feature of the disease should be used to', 'help determine the sPGA score. See Appendix C for grading criteria.', '6.4.3.', 'Scalp Physician Global Assessment (ScPGA)', 'The ScPGA will assess scalp involvement. See Appendix D for grading criteria. The', '5-point ScPGA scale ranges from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to', '4 (severe).', '6.4.4.', 'Nail Assessments/Nail Psoriasis Severity Index (NAPSI)', 'The number of fingers with psoriasis nail involvement, defined as onycholysis and', 'onychodystrophy, will be counted.', 'The NAPSI will assess one target thumb nail or fingernail representing the worst nail', 'psoriasis involvement at Baseline. See Appendix E for grading criteria.', '6.4.5.', 'Modified static Physicians Global Assessment of Genitalia (Modified sPGA-G)', 'The modified sPGA-G is the assessment by the Investigator of the overall disease', 'severity at the time of evaluation of the genital regions. The assessment area includes', 'the vulvar region in women, from the clitoral prepuce to the perineum, and the penis,', 'scrotum, and perineum in men. It does not include the pubis, inguinal folds, peri-anal', 'region, or gluteal cleft; however, in this study, the assessment will be modified to also', 'include the peri-anal region and gluteal cleft. As with the sPGA, it is a 5-point scale,', 'ranging from 0 (clear) to 4 (severe). Note that not all three individual features will', 'always be present on evaluation. Thus, while the total represents a combination of the', 'Confidential and Proprietary', '35', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'three features, it should be primarily determined by the degree of erythema, as that is', 'the dominant feature in the majority of cases of genital psoriasis (Merola, 2017).', 'Appendix F.', '6.4.6.', 'Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', 'The PPPGA is the assessment by the Investigator of the overall disease severity at the', 'time of evaluation of palms and soles (Leonardi, 2007). The scale ranges from', 'ranging from 0 (clear) to 4 (severe). See Appendix G.', '6.4.7.', 'Itch Numeric Rating Scale (NRS)', 'The Itch NRS is a single-item patient-reported outcome that asks subjects to assess', 'the worst severity of itch over the past 24 hours. Subjects indicate itch severity by', 'circling the number that best describes the worst level of itching due to psoriasis in', 'the past 24 hours on an 11-point scale anchored at 0, representing \"no itching\\' and 10,', 'representing \"worst itch imaginable\\' (Naegeli, 2015). See Appendix H.', '6.4.8.', 'Skin Discomfort/Pain Visual Analog Scale (VAS)', 'The subject will be asked to place a vertical stroke on a 100 mm VAS on which the', 'left-hand boundary represents no skin discomfort/pain, and the right-hand boundary', 'represents skin discomfort/pain as severe as can be imagined. The distance from the', 'mark to the left-hand boundary will be recorded. See Appendix I.', '6.4.9.', 'Body Surface Area (BSA)', 'Body surface area is a measurement of involved skin. The overall BSA affected by', \"psoriasis is estimated based on the palm area of the subject's hand (entire palmar\", 'surface or \"handprint\"), which equates to approximately 1% of total BSA.', '6.4.10.', 'Psoriasis Area Severity Index (PASI)', 'The PASI will be determined for all subjects throughout the study. The PASI', 'calculation is described in Appendix J.', 'The PASI is a measure of psoriatic disease severity taking into account qualitative', 'lesion characteristics (erythema, thickness, and scaling) and degree of skin surface', 'area involvement on defined anatomical regions. The PASI is a validated instrument', 'that has become standard in clinical trials for psoriasis.', 'The PASI scores range from 0 to 72, with higher scores reflecting greater disease', 'severity (Fredriksson, 1978). Erythema, thickness, and scaling are scored on a scale', 'of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper', 'limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is', 'scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The total', 'qualitative score (sum of erythema, thickness, and scaling scores) is multiplied by the', 'degree of involvement for each anatomic region and then multiplied by a constant.', 'These values for each anatomic region are summed to yield the PASI score.', 'Confidential and Proprietary', '36', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']", "completion": ""}